FindTrial
Sign In

Application of FAPI-based positron imaging agents in tumor diagnosis, curative effect monitoring and treatment

Application of FAPI-based positron imaging agents in tumor diagnosis, curative effect monitoring and treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044944
Enrollment
Unknown
Registered
2021-04-01
Start date
2020-05-01
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor

Interventions

Gold Standard:18F-FDG
Index test:NOTA-FAPI

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent form voluntarily; 2. Patients with suspected malignant tumors but no pathological results; 3. Patients with diagnosed malignant tumors; 4. For patients with malignant tumors after treatment, evaluate the treatment effect.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients; 2. Critical emergency patients, respiratory depression, (pulmonary) airway obstruction, or tissue hypoxia; 3. Drug and (or) alcohol abusers, people with allergies; 4. Those who cannot tolerate and cooperate with the inspection; 5. Those who are judged by the researcher to be unsuitable to participate in this research.

Design outcomes

Primary

MeasureTime frame
SUVmax;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactXinlu Wang

The First Affiliated Hospital of Guangzhou Medical University

71lu@163.com+86 20 34297835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026